• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number UNK SJM TRIFECTA VALVE
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Aortic Valve Stenosis (1717); Stroke/CVA (1770); Unspecified Infection (1930); Transient Ischemic Attack (2109); Heart Block (4444); Heart Failure/Congestive Heart Failure (4446); Aortic Valve Insufficiency/ Regurgitation (4450)
Event Date 06/01/2014
Event Type  Injury  
Manufacturer Narrative
B3 - date of event is estimated.D4 - the udi number is not known as the part and lot numbers were not provided.The additional patient effects of death and malfunctions reported in the article are captured under separate medwatch reports.Summarized patient outcomes/complications of trifecta valve in middle age population with small aortic annuls were reported in a research article "mid-term clinical and hemodynamic outcomes in middle age patients post trifecta¿ (abbott) aortic valve replacement: a single-center study" in a subject population with multiple co-morbidities including smoking, hypertension, diabetes mellitus, dyslipidemia, chronic obstructive pulmonary disease, cancer, renal failure, peripheral vascular disease including deep vein thrombosis and left iliac and renal embolization, prior cerebrovascular accident, chronic atrial fibrillation, myocardial infarction, angina, coronary artery disease, prior cardiac procedures, heart failure.Some of the complications reported were death, surgical intervention (surgical explant, valve-in-valve), hospitalization (30-day readmission), transient ischemic attack, cerebrovascular accident, atrioventricular block, infection, aortic stenosis, aortic regurgitation, paravalvular leak; these complications are anticipated for the procedure and subject population.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device or individual patient information was received for analysis.
 
Event Description
The article, "mid-term clinical and hemodynamic outcomes in middle age patients post trifecta¿ (abbott) aortic valve replacement: a single-center study", was reviewed.The article presented a retrospective, single center study on the mid-term clinical and hemodynamic performance of trifecta valve in middle age population with small aortic annuls.The only device included in this study was trifecta valve.The article concluded excellent mid-term durability, clinical and hemodynamic performance of the trifecta valve in middle age population, despite the fact of non-statically significant trend-up of transvalvular gradient over the follow up period.Further long-term studies with larger sample-size are warranted to confirm these results.[the primary and corresponding author was mohammed al aboud, adult cardiac surgery section, heart center, king faisal specialist hospital and research centre, riyadh, saudi arabia, with corresponding email: : mohd.Alaboud@gmail.Com].The time frame of the study was from june 2014 to december 2019 with last follow up on (b)(6) 2023.A total of 24 patients were included in this study, of which all received an abbott device.The average age was 47 years and there was no majority gender (evenly divided out of 24 patients).Comorbidities included smoking, hypertension, diabetes mellitus, dyslipidemia, chronic obstructive pulmonary disease, cancer, renal failure, peripheral vascular disease including deep vein thrombosis and left iliac and renal embolization, prior cerebrovascular accident, chronic atrial fibrillation, myocardial infarction, angina, coronary artery disease, prior cardiac procedures, heart failure.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SJM TRIFECTA VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key19187896
MDR Text Key341117098
Report Number2135147-2024-01848
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeSA
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 04/25/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK SJM TRIFECTA VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 04/04/2024
Initial Date FDA Received04/25/2024
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Life Threatening; Disability; Required Intervention;
-
-